Type of security: Stock
Sector: Basic Industries
Industry: Major Chemicals
The data is delayed by 15 minutes.
Description: Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
|Shares Outstanding||EPS||-0.23||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||3.47%||Sales Growth - Q/Q||-52.1%||P/E||-20.87|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-44.08%||ROE||-84.46%||ROI|
|Current Ratio||2.33||Quick Ratio||2.24||Long Term Debt/Equity||Debt Ratio||0.55|
|Gross Margin||75.28%||Operating Margin||-52.08%||Net Profit Margin||-52.12%||Dividend Payout Ratio|
|Cash From Financing Activities||-430 K||Cash From Investing Activities||-60 K||Cash From Operating Activities||-3.84 M||Gross Profit||5.34 M|
|Net Profit||-5.56 M||Operating Profit||-5.53 M||Total Assets||41.42 M||Total Current Assets||27.63 M|
|Total Current Liabilities||11.87 M||Total Debt||Total Liabilities||19.8 M||Total Revenue||6.8 M|
|High 52 week||22.57||Low 52 week||13.35||Last close||14.17||Last change||0.07%|
|RSI||15.42||Average true range||0.74||Beta||1.16||Volume||24.04 K|
|Simple moving average 20 days||-19.88%||Simple moving average 50 days||-21.48%||Simple moving average 200 days||-24.42%|
|Performance Week||-19.31%||Performance Month||-24.39%||Performance Quart||-28.29%||Performance Half||-34.15%|
|Performance Year||6.14%||Performance Year-to-date||-15.15%||Volatility daily||3.98%||Volatility weekly||8.89%|
|Volatility monthly||18.22%||Volatility yearly||63.12%||Relative Volume||202.67%||Average Volume||386.81 K|
|New High||New Low|
2020-05-22 19:31:54 | Should Codexis Investors Prepare for Slower Growth?
2020-05-11 07:00:10 | Codexis to Present at the UBS Virtual Healthcare Conference
2020-05-11 06:51:41 | H.C. Wainwright Sticks to Their Buy Rating for Codexis
2020-05-09 01:30:56 | CodexisCDXS Q1 2020 Earnings Call Transcript
2020-05-08 14:13:52 | Edited Transcript of CDXS earnings conference call or presentation 7-May-20 8:30pm GMT
2020-05-07 16:05:10 | Codexis Reports First Quarter 2020 Financial Results
2020-05-06 16:05:10 | Codexis Achieves Technology Transfer Milestone with Global Pharmaceutical Leader
2020-05-05 07:00:10 | Codexis Expands and Strengthens its Leadership Team with Two Executive Hires
2020-04-30 07:00:10 | Codexis to Hold First Quarter 2020 Conference Call on May 7
2020-04-27 12:31:04 | Earnings Preview: Codexis CDXS Q1 Earnings Expected to Decline
2020-04-07 08:37:23 | Is Codexis, Inc.'s NASDAQ:CDXS CEO Pay Justified?
2020-03-13 13:57:07 | Edited Transcript of CDXS earnings conference call or presentation 27-Feb-20 9:30pm GMT
2020-03-02 10:15:03 | Company News for Mar 2, 2020
2020-03-01 07:19:54 | Analysts Have Been Trimming Their Codexis, Inc. Price Target After Its Latest Report
2020-02-27 18:55:11 | Codexis CDXS Q4 Earnings and Revenues Lag Estimates
2020-02-27 16:05:10 | Codexis Reports 2019 Fourth Quarter and Full Year Financial Results
2020-02-25 07:00:10 | Codexis to Present at Two Investment Conferences in March
2020-02-20 07:00:10 | Codexis to Hold 2019 Fourth Quarter and Full Year Conference Call on February 27
2020-01-31 07:52:55 | Have Insiders Been Buying Codexis, Inc. NASDAQ:CDXS Shares This Year?
2020-01-13 16:05:10 | Codexis Attends Opening Ceremony for Porton’s Fermentation Pilot Lab in Chongqing
2020-01-01 09:06:21 | We're Not Very Worried About Codexis's NASDAQ:CDXS Cash Burn Rate
2019-12-16 06:10:17 | Hedge Funds Are Dumping Codexis, Inc. CDXS
2019-12-02 12:32:50 | Codexis NASDAQ:CDXS Shareholders Have Enjoyed A Whopping 567% Share Price Gain
2019-11-06 09:00:02 | Codexis CDXS Upgraded to Buy: What Does It Mean for the Stock?
2019-11-06 06:08:24 | Edited Transcript of CDXS earnings conference call or presentation 5-Nov-19 9:30pm GMT
2019-11-05 19:55:12 | Codexis CDXS Q3 Earnings and Revenues Beat Estimates
2019-11-05 16:05:00 | Codexis Reports Third Quarter 2019 Financial Results
2019-11-05 07:00:05 | Codexis to Participate in Four Investment Conferences in November
2019-10-29 07:00:05 | Codexis to Hold Third Quarter 2019 Conference Call on November 5
2019-10-27 20:13:14 | Is Codexis, Inc. CDXS A Good Stock To Buy ?
2019-10-26 09:13:00 | A Look At The Fair Value Of Codexis, Inc. NASDAQ:CDXS
2019-10-15 16:05:00 | Codexis’ Protein Engineering Forum Highlights Progress and Future Direction of the Field
2019-09-26 08:00:00 | Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit
2019-09-26 07:00:00 | Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
2019-09-20 06:57:54 | Is Codexis, Inc.'s NASDAQ:CDXS CEO Pay Justified?
2019-08-29 07:11:00 | 3 Top Stocks Under $20
2019-08-22 23:15:03 | Codexis Inc CDXS President and CEO John J Nicols Bought $133,000 of Shares
2019-08-09 13:32:50 | Edited Transcript of CDXS earnings conference call or presentation 6-Aug-19 8:30pm GMT
2019-08-07 15:49:08 | Codexis Rolls Into Second Half Armed with Cash
2019-08-07 08:25:49 | CodexisCDXS Q2 2019 Earnings Call Transcript
2019-08-06 19:35:11 | Codexis CDXS Reports Q2 Loss, Lags Revenue Estimates
2019-08-06 16:06:00 | Codexis Reports Second Quarter 2019 Financial Results
2019-07-30 07:00:00 | Codexis to Hold Second Quarter 2019 Conference Call on August 6
2019-06-27 15:01:00 | 3 Top Stocks Under $20
2019-06-20 07:00:00 | Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives